Atherectomy

Global Pediatric Interventional Cardiology Market Forecast 2024-2030: PIC Market Forecast for 6.36% CAGR Between 2024 to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024

The Pediatric Interventional Cardiology Market is forecasted to reach US$ 3.91 Billion through 2030.

Key Points: 
  • The Pediatric Interventional Cardiology Market is forecasted to reach US$ 3.91 Billion through 2030.
  • The pediatric interventional cardiology market proportion is expanding swiftly, driven by the rising prevalence of cardiac disorders in children and technological advancements.
  • The Stents segment is anticipated to dominate the global pediatric interventional cardiology market throughout the forecast period.
  • The comprehensive infrastructure of hospitals, coupled with their ability to provide diverse pediatric cardiology services, positions them as key contributors to the growth and development of the Pediatric Interventional Cardiology market.

Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions

Retrieved on: 
Thursday, March 7, 2024

This collaboration also provides Avinger the opportunity to distribute high-quality peripheral vascular products developed by Zylox-Tonbridge in the United States and Germany.

Key Points: 
  • This collaboration also provides Avinger the opportunity to distribute high-quality peripheral vascular products developed by Zylox-Tonbridge in the United States and Germany.
  • Avinger is globally recognized for its pioneering OCT-guided, catheter-based system and devices, offering real-time intra-vascular imaging during treatment.
  • By collaborating with Avinger, Zylox-Tonbridge is introducing the globally leading OCT-guided vascular treatment technology to the Chinese peripheral intervention market.
  • We believe this collaboration will expand the company's Peripheral Vascular Intervention product portfolio, reinforcing our market leadership, and accelerating the growth of the vessel preparation business in China's peripheral vascular intervention market.

AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease

Retrieved on: 
Tuesday, January 23, 2024

According to the American Heart Association, PAD affects 8.5 million Americans and 200 million people worldwide each year1.

Key Points: 
  • According to the American Heart Association, PAD affects 8.5 million Americans and 200 million people worldwide each year1.
  • Studies have shown that radial access is associated with a significantly lower risk of major bleeding and access site complications when compared to femoral access2,3 in the treatment of patients.
  • Use of a general radial access catheter may reduce incidents of major bleeding, when compared to femoral access, by more than 70%3.
  • The technology underlying the Auryon Atherectomy System has been shown in clinical studies to be effective in treating lesions ranging from soft plaque to severely calcified5,6,8.

Global Atherectomy Devices Market Report 2023-2030: Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunities, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, January 8, 2024

The "Atherectomy Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Atherectomy Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Atherectomy devices are minimally invasive medical devices that are used to eliminate plaque build-up from the partitions of arteries.
  • By Product Type, Global Atherectomy Devices Market is divided into Directional Atherectomy, Rotational Atherectomy, Orbital Atherectomy and Laser Atherectomy.
  • Hospitals are poised to maintain their stronghold with the very best market proportion in the Atherectomy Devices Market.

Digital Health Market Worth $549.7 Billion | MarketsandMarkets

Retrieved on: 
Tuesday, November 14, 2023

Based on technology, the digital health market is segmented into telehealthcare, mHealth, health management solutions and digital therapeutics.

Key Points: 
  • Based on technology, the digital health market is segmented into telehealthcare, mHealth, health management solutions and digital therapeutics.
  • On the basis of application, the digital health market is segmented into chronic disease management, behavioral health, health & fitness and others.
  • ·  Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the digital health market.
  • ·  Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the digital health market.

Digital Health Market Worth $549.7 Billion | MarketsandMarkets

Retrieved on: 
Tuesday, November 14, 2023

Based on technology, the digital health market is segmented into telehealthcare, mHealth, health management solutions and digital therapeutics.

Key Points: 
  • Based on technology, the digital health market is segmented into telehealthcare, mHealth, health management solutions and digital therapeutics.
  • On the basis of application, the digital health market is segmented into chronic disease management, behavioral health, health & fitness and others.
  • ·  Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the digital health market.
  • ·  Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the digital health market.

Cardio Flow Announces Completion of First Commercial Cases of Innovative FreedomFlow Orbital Atherectomy Platform—and Appointment of Chief Operating Officer

Retrieved on: 
Monday, October 30, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231027207271/en/
    Cardio Flow announced the successful completion of its first commercial cases in leading medical centers across the U.S.
  • Michael Kallok, Ph.D., CEO of Cardio Flow, also announced the appointment of Scott Kraus as Chief Operating Officer.
  • Most recently, Scott served as Vice President of Sales & Marketing for Cardio Flow and was responsible for overseeing all commercial functions.
  • Most notably, he was part of the commercial team at CSI that launched the orbital atherectomy systems.

First Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Tuesday, October 31, 2023

Below are highlights of this morning's 5 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 5 late-breaking clinical trial presentations.
  • At 20 centers without roll-ins across the United States, 105 no-option CLTI patients were enrolled in a nonrandomized manner.
  • The median age was 70 years, two-thirds of the patients were male, and one-quarter of patients were Hispanic or Latino.
  • 1-Year Results of the DEEPER OUS Trial: The Bare Temporary Spur Stent System in Combination With a Paclitaxel-Coated Balloon
    The DEEPER OUS trial is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland.

New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

Retrieved on: 
Thursday, October 19, 2023

The publications each reported separate patient-level pooled optical coherence tomography (OCT) sub-analyses of the company-sponsored Disrupt CAD clinical studies.

Key Points: 
  • The publications each reported separate patient-level pooled optical coherence tomography (OCT) sub-analyses of the company-sponsored Disrupt CAD clinical studies.
  • “While the majority of the robust, core-lab adjudicated evidence supporting coronary IVL to date has studied concentric calcium, we are beginning to see a shift in evidence reinforcing IVL use across all calcium morphologies, both in retrospective analyses and ‘real-world’ prospective registries,” said Keith D. Dawkins, MD, Chief Medical Officer of Shockwave Medical.
  • While there were no differences in pre-procedure minimum lumen area (MLA), diameter stenosis, or maximum calcium thickness across the different calcium arcs, the calcium length and overall volume index increased progressively with concentric calcium, and a higher minimum calcium thickness was increased with eccentric calcium.
  • “Given the relatively low prevalence of nodules, it has been challenging to perform large prospective controlled studies.

Cardio Flow, Inc., Announces U.S. Food and Drug Administration (FDA) 510(k) Clearance for its FreedomFlow® Orbital Atherectomy Peripheral Platform

Retrieved on: 
Wednesday, October 18, 2023

Cardio Flow, Inc. , a privately held medical device company and developer of minimally invasive devices to treat peripheral artery disease (PAD), today announced it recently received U.S. Food and Drug Administration (FDA) 510(k) clearance for the company’s FreedomFlow Orbital Atherectomy Peripheral Platform.

Key Points: 
  • Cardio Flow, Inc. , a privately held medical device company and developer of minimally invasive devices to treat peripheral artery disease (PAD), today announced it recently received U.S. Food and Drug Administration (FDA) 510(k) clearance for the company’s FreedomFlow Orbital Atherectomy Peripheral Platform.
  • The simplicity of the FreedomFlow platform likewise offers time savings and cost efficiencies, with quick and simple device setup, no capital equipment, no lubricant, and reduced inventory needs.
  • Many of the existing atherectomy devices on the market have various design constraints and capital equipment costs.
  • We’re excited that FreedomFlow will now be available to physicians.”